Efficacy and Safety of Early Versus Delayed Administration of Everolimus in de Novo Renal Transplant Patients

NCT00154297 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

139

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Transplantation

Interventions

DRUG: Everolimus (RAD001)

Sponsor

Novartis Pharmaceuticals